	US 12,383,582 B2
	Methods of treating chronic wounds with amniotic fluid having elevated levels of tissue inhibitors of matrix metalloproteinases
Jeffrey S. White, Chester Springs, PA (US)
Assigned to Prime Merger Sub, LLC, Birmingham, AL (US)
Filed by Prime Merger Sub, LLC, Birmingham, AL (US)
Filed on Sep. 1, 2021, as Appl. No. 17/464,340.
Application 17/464,340 is a continuation of application No. 15/059,558, filed on Mar. 3, 2016, granted, now 11,129,856.
Claims priority of provisional application 62/127,433, filed on Mar. 3, 2015.
Prior Publication US 2021/0393702 A1, Dec. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/50 (2015.01); A61K 45/06 (2006.01); C12Q 1/37 (2006.01)

CPC A61K 35/50 (2013.01) [A61K 45/06 (2013.01); C12Q 1/37 (2013.01); G01N 2333/96494 (2013.01)]

20 Claims

1. A method of treating a chronic wound in a subject comprising:

processing a human amniotic fluid; and

applying the processed human amniotic fluid comprising a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) to the chronic wound, thereby treating the chronic wound,

wherein processing the human amniotic fluid comprises filtering particulate matter from the human amniotic fluid, the particulate matter being selected from the group consisting of cellular debris, tissue debris, and both cellular debris and tissue debris.